Popular Weight-Lifting Supplement May Slow Huntington Disease, Massachusetts General Hospital Study

Published: Feb 11, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The first clinical trial of a drug intended to delay the onset of symptoms of Huntington disease (HD) reveals that high-dose treatment with the nutritional supplement creatine was safe and well tolerated by most study participants. In addition, neuroimaging showed a treatment-associated slowing of regional brain atrophy, evidence that creatine might slow the progression of presymptomatic HD. The Massachusetts General Hospital (MGH) study also utilized a novel design that allowed participants – all of whom were at genetic risk for the neurodegenerative disorder – to enroll without having to learn whether or not they carried the mutation that causes HD.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news